DexCom (NASDAQ:DXCM) Price Target Lowered to $113.00 at Barclays

DexCom (NASDAQ:DXCM) had its price objective reduced by Barclays from $138.00 to $113.00 in a report issued on Monday morning, Benzinga reports. They currently have an equal weight rating on the medical device company’s stock.

Other equities analysts also recently issued research reports about the company. Citigroup lifted their price target on DexCom from $148.00 to $161.00 and gave the company a buy rating in a research note on Wednesday, April 3rd. Stifel Nicolaus cut their target price on DexCom from $132.00 to $90.00 and set a buy rating on the stock in a research note on Friday, July 26th. Redburn Atlantic started coverage on DexCom in a research note on Thursday, May 30th. They issued a neutral rating and a $130.00 target price on the stock. StockNews.com downgraded DexCom from a buy rating to a hold rating in a research note on Monday, June 10th. Finally, Piper Sandler cut their target price on DexCom from $150.00 to $90.00 and set an overweight rating on the stock in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $111.50.

DexCom Price Performance

DXCM stock opened at $70.32 on Monday. The company has a market capitalization of $28.18 billion, a P/E ratio of 45.37, a price-to-earnings-growth ratio of 2.10 and a beta of 1.16. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom has a 52-week low of $62.34 and a 52-week high of $142.00. The business has a 50-day simple moving average of $110.43 and a two-hundred day simple moving average of $122.19.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.34 EPS. Research analysts expect that DexCom will post 1.69 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,135 shares of company stock valued at $446,797. 0.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DXCM. Fifth Third Bancorp grew its position in DexCom by 12.8% in the fourth quarter. Fifth Third Bancorp now owns 25,429 shares of the medical device company’s stock worth $3,155,000 after acquiring an additional 2,894 shares in the last quarter. Patten & Patten Inc. TN grew its position in DexCom by 1.8% in the fourth quarter. Patten & Patten Inc. TN now owns 46,122 shares of the medical device company’s stock worth $5,723,000 after acquiring an additional 825 shares in the last quarter. WoodTrust Financial Corp grew its position in DexCom by 5.0% in the fourth quarter. WoodTrust Financial Corp now owns 12,560 shares of the medical device company’s stock worth $1,558,000 after acquiring an additional 600 shares in the last quarter. International Assets Investment Management LLC purchased a new position in DexCom in the fourth quarter worth $1,986,000. Finally, Capital Insight Partners LLC grew its position in DexCom by 11.0% in the fourth quarter. Capital Insight Partners LLC now owns 2,548 shares of the medical device company’s stock worth $316,000 after acquiring an additional 252 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.